The Medyzen blog
Clinical Drug Insights
Epilepsy drug names explained by generic class, not brand: which antiseizure medicines sit on India's essential medicines list and why generic names matter more.
Clinical Drug Insights
A clinical overview of epilepsy drug classes used in India, why the treatment gap runs as high as 90% in rural areas, and what drives cost variation.
Clinical Drug Insights
Why drug shortages happen in India — API import dependence, NPPA price control, recalls — and how hospital pharmacies build resilience against them.
Compliance
Which drug licence form your pharmacy needs, the ONDLS application process, real fees, documents, and why applications actually get rejected.
Setup Guides
Every document needed for a retail drug licence in India, from pharmacist registration to premises proof, with the exact forms and what trips up applications.
Clinical Drug Insights
The medicines actually used in dengue management in India — paracetamol brands, ORS formulations, IV fluids and platelet support — per NVBDCP guidelines.
Clinical Drug Insights
Why dengue's sharp seasonal surge makes hospital pharmacy and blood-bank stocking reliability a bigger factor in outcomes than most administrators plan for.
Clinical Drug Insights
How WHO's 2009 dengue classification and India's NVBDCP/IDSP framework structure dengue guidelines, notifiable-disease reporting and hospital compliance.
Clinical Drug Insights
How dengue is actually managed in Indian hospitals: NVBDCP phases, fluid protocols, platelet thresholds, warning signs and what current guidelines say.
Clinical Drug Insights
Why NSAIDs, aspirin and antiplatelet drugs are contraindicated in dengue, per MoHFW's national clinical guidelines, and what interacts with what.
Clinical Drug Insights
A breakdown of what dengue treatment actually costs in India — testing, platelet transfusion, hospitalisation days, and where state price caps apply.
Clinical Drug Insights
COVID drug names used in India — remdesivir, molnupiravir, favipiravir, dexamethasone — and which ones MoHFW's 2023 protocol still recommends.
Clinical Drug Insights
The COVID-19 drugs actually approved and in clinical use in India — molnupiravir, nirmatrelvir/ritonavir, remdesivir — per CDSCO and AIIMS/ICMR protocol.
Clinical Drug Insights
Cortisone shot side effects by incidence rate: skin atrophy, tendon rupture, infection risk, and blood glucose spikes in diabetic patients, sourced from peer-reviewed data.
Clinical Drug Insights
The inhaler and drug classes behind COPD treatment names used in India, per GOLD and Indian ICS/NCCP guidelines, and what each class actually does.
Clinical Drug Insights
Why COPD inhaler availability in Indian hospital pharmacies depends on device type, storage, NPPA pricing and Jan Aushadhi stock, not just molecule.
Clinical Drug Insights
COPD treatment guidelines compared: the global GOLD 2026 report and India's ICS/NCCP consensus guidelines, plus how NPCDCS integrates COPD care.
Clinical Drug Insights
How COPD is actually treated per GOLD guidelines, India's real disease burden data, air pollution's role, and NPPA-regulated inhaler pricing.
Clinical Drug Insights
COPD drug interactions doctors miss most: theophylline with macrolides/fluoroquinolones, beta blockers with LABAs, and tiotropium's anticholinergic overlap.
Clinical Drug Insights
What drives COPD treatment cost in India: inhaler pricing under DPCO, PM-JAY hospitalisation rates, and why inhaler affordability remains a real gap.
Setup Guides
Registration, drug licensing, biomedical waste authorisation, layout and essential stock for a clinic or nursing home pharmacy in India, in the right order.
Clinical Drug Insights
Chemotherapy drugs used in India by class, NPPA price control on anti-cancer medicines, Jan Aushadhi generic access, and hospital cold-chain handling rules.
Costs & Economics
Real retailer margins on branded vs generic medicines in India, why chemists push generics, and how a pharmacy should actually decide what to stock.
Clinical Drug Insights
What peer-reviewed evidence actually supports for natural, nutrition-based fracture healing support in India, and where the evidence runs out.
